{
  "items": "30",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential",
      "url": "https://ca.investing.com/news/analyst-ratings/guggenheim-initiates-sab-biotherapeutics-stock-with-buy-rating-on-t1d-potential-93CH-4373371",
      "time_published": "20251219T120852",
      "authors": [
        "Investing.com"
      ],
      "summary": "Guggenheim has initiated coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and a $15.00 price target, suggesting a significant upside. The firm highlights SAB-142, a therapy for Stage 3 Type 1 Diabetes, as a key asset with potential for $2 billion in peak global sales. This comes amidst other positive developments for the company, including recent shareholder approvals and maintained Buy ratings from other analysts.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_8_800x533_L_1420026210.jpg",
      "source": "Investing.com Canada",
      "category_within_source": "General",
      "source_domain": "Investing.com Canada",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.922183"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.835286"
        },
        {
          "topic": "finance",
          "relevance_score": "0.624683"
        }
      ],
      "overall_sentiment_score": 0.640763,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.624562",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Chardan Capital Maintains SAB Biotherapeutics (SABS) Buy Recommendation",
      "url": "https://www.nasdaq.com/articles/chardan-capital-maintains-sab-biotherapeutics-sabs-buy-recommendation-0",
      "time_published": "20251218T200852",
      "authors": [
        "George Maybach for Fintel"
      ],
      "summary": "Chardan Capital has maintained its Buy recommendation for SAB Biotherapeutics (SABS) with an average one-year price target of $9.01/share, suggesting a 129.26% upside. The company is projected to see significant revenue growth and institutional ownership has increased, indicating a bullish outlook. Major institutional holders include Vivo Capital, Commodore Capital, and Ra Capital Management.",
      "banner_image": "https://www.nasdaq.com/sites/acquia.prod/files/2022/05/24/fintel-f-logo.jpg",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.908986"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.843401"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.706003"
        },
        {
          "topic": "finance",
          "relevance_score": "0.623984"
        }
      ],
      "overall_sentiment_score": 0.745362,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.716753",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "First Patient Dosed in SAB BIO\u2019s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D",
      "url": "https://www.globenewswire.com/news-release/2025/12/18/3207653/0/en/First-Patient-Dosed-in-SAB-BIO-s-SAFEGUARD-Clinical-Trial-of-SAB-142-for-the-Treatment-of-Stage-3-T1D.html",
      "time_published": "20251218T130903",
      "authors": [
        "NULL"
      ],
      "summary": "SAB Biotherapeutics, Inc. announced the dosing of the first patient in its Phase 2b SAFEGUARD clinical trial for SAB-142, a human anti-thymocyte immunoglobulin (hATG) for stage 3 type 1 diabetes (T1D). This milestone advances their \"Beyond Insulin\" vision for a disease-modifying therapy. The company anticipates sharing Phase 2b data in the second half of 2027 while actively enrolling patients globally.",
      "banner_image": "https://ml.globenewswire.com/media/OTQwYTgxOWMtZjU3Ni00OTE2LTkyNTItMjY5MWE5Nzc4NTFlLTEyMzMyOTQtMjAyNS0xMi0xOC1lbg==/tiny/SAB-Biotherapeutics-Inc-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.544552,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.530023",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB Biotherapeutics' (SABS) Buy Rating Reiterated at Chardan Capital",
      "url": "https://www.marketbeat.com/instant-alerts/sab-biotherapeutics-sabs-buy-rating-reiterated-at-chardan-capital-2025-12-18/",
      "time_published": "20251218T130903",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Chardan Capital has reiterated a \"buy\" rating for SAB Biotherapeutics (NASDAQ:SABS), setting a target price of $12.00, which suggests a potential upside of 203% from its previous close. Despite a consensus \"Moderate Buy\" rating from analysts with an average target of $9.33, the company recently exceeded quarterly EPS estimates, though analysts project a negative EPS for the current fiscal year. The stock opened at $3.96 with a market cap of approximately $188.5 million.",
      "banner_image": "https://www.marketbeat.com/logos/sab-biotherapeutics-logo-1200x675.png?v=20211202075708",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.918742"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.905990"
        },
        {
          "topic": "finance",
          "relevance_score": "0.814723"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.729567"
        }
      ],
      "overall_sentiment_score": 0.413778,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.409276",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D",
      "url": "https://investingnews.com/sab-bio-announces-positive-confirmatory-clinical-results-from-the-phase-1-study-of-sab-142-in-development-for-the-treatment-of-stage-3-t1d/",
      "time_published": "20251217T140908",
      "authors": [
        "Investing News Network"
      ],
      "summary": "SAB Biotherapeutics (Nasdaq: SABS) announced positive confirmatory data from its Phase 1 trial of SAB-142 for Stage 3 Type 1 Diabetes (T1D), demonstrating a superior safety profile with no serum sickness or anti-drug antibody-associated adverse events. The study supports chronic dosing of SAB-142 and has enabled its advancement into the Phase 2b SAFEGUARD trial, now recruiting globally. SAB-142 is positioned as a potential best-in-class, redosable treatment to delay T1D progression due to its transient lymphopenia and potential for safe re-administration.",
      "banner_image": "https://investingnews.com/media-library/image.gif?id=29654756&width=1200&height=1200",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.948346"
        },
        {
          "topic": "finance",
          "relevance_score": "0.728755"
        }
      ],
      "overall_sentiment_score": 0.81197,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.821398",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB Biotherapeutics Confirms Positive Phase 1 Results for SAB-142, Advancing to Phase 2b Trial for Type 1 Diabetes Treatment",
      "url": "https://www.quiverquant.com/news/SAB+Biotherapeutics+Confirms+Positive+Phase+1+Results+for+SAB-142%2C+Advancing+to+Phase+2b+Trial+for+Type+1+Diabetes+Treatment",
      "time_published": "20251217T131700",
      "authors": [
        "NULL"
      ],
      "summary": "SAB Biotherapeutics announced positive Phase 1 results for SAB-142, an investigational drug for type 1 diabetes (T1D). The trial confirmed SAB-142's safety and tolerability, with no serum sickness or significant immunogenicity observed, and only mild side effects. These findings support the drug's advancement to a Phase 2b SAFEGUARD trial, which is currently enrolling participants globally and aims to assess efficacy in adult and pediatric T1D patients.",
      "banner_image": "https://www.globenewswire.com/NewsRoom/AttachmentNg/56c69165-5952-46ec-adb4-af37827914a8",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.917068"
        }
      ],
      "overall_sentiment_score": 0.617367,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.624298",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB BIO Announces Positive Confirmatory Clinical Results",
      "url": "https://www.globenewswire.com/news-release/2025/12/17/3206921/0/en/SAB-BIO-Announces-Positive-Confirmatory-Clinical-Results-from-the-Phase-1-Study-of-SAB-142-in-Development-for-the-Treatment-of-Stage-3-T1D.html",
      "time_published": "20251217T130908",
      "authors": [
        "NULL"
      ],
      "summary": "SAB Biotherapeutics announced positive confirmatory data from a Phase 1 trial of SAB-142 for the treatment of Stage 3 Type 1 Diabetes (T1D). The study demonstrated that SAB-142 does not cause serum sickness and has low/no immunogenicity, supporting its potential for chronic dosing in an outpatient setting. This successful outcome allows the company to advance SAB-142 into the Phase 2b SAFEGUARD trial, which is currently recruiting patients globally.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/56c69165-5952-46ec-adb4-af37827914a8/sab-table1.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.880038,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.880355",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management",
      "url": "https://www.manilatimes.net/2025/12/08/tmt-newswire/globenewswire/sab-bio-to-present-data-showcasing-progress-in-the-development-of-sab-142-at-the-asian-conference-on-innovative-therapies-for-diabetes-management/2238944",
      "time_published": "20251208T230858",
      "authors": [
        "GlobeNewswire"
      ],
      "summary": "SAB Biotherapeutics, Inc. (Nasdaq: SABS) will present data on its lead program, SAB-142, at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) from December 9-11, 2025, in Singapore. The presentations will highlight Phase 1 study data demonstrating SAB-142's multi-specific mechanism of action, immunomodulation without sustained lymphodepletion, and a favorable safety profile for delaying the progression of Type 1 Diabetes (T1D). SAB-142 is a potentially best-in-class, disease-modifying, redosable immunotherapy currently in Phase 2b clinical development.",
      "banner_image": "https://ml.globenewswire.com/media/OWExOTZhYzAtYzgzOS00OGJhLTllNWUtNWUwM2MwZGUwZTE3LTEyMzMyOTQtMjAyNS0xMi0wOC1lbg==/tiny/SAB-Biotherapeutics-Inc-.png",
      "source": "The Manila Times",
      "category_within_source": "General",
      "source_domain": "The Manila Times",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925671"
        },
        {
          "topic": "finance",
          "relevance_score": "0.633987"
        }
      ],
      "overall_sentiment_score": 0.488054,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.482716",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management",
      "url": "https://investingnews.com/sab-bio-to-present-data-showcasing-progress-in-the-development-of-sab-142-at-the-asian-conference-on-innovative-therapies-for-diabetes-management/",
      "time_published": "20251208T140925",
      "authors": [
        "NULL"
      ],
      "summary": "SAB Biotherapeutics, Inc. will present data on its lead program, SAB-142, at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) from December 9-11, 2025. The presentations will highlight Phase 1 study data demonstrating SAB-142's multi-specific mechanism of action, immunomodulation without sustained lymphodepletion, and a favorable safety profile for delaying the progression of Type 1 Diabetes in new-onset, Stage 3 patients. These findings support SAB-142's development as a potential best-in-class immunotherapy, currently in Phase 2b clinical trials.",
      "banner_image": "https://investingnews.com/media-library/image.gif?id=29654756&width=1200&height=1200",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.904081"
        }
      ],
      "overall_sentiment_score": 0.433928,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.419048",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB Biotherapeutics to Present Data on SAB-142 for Type 1 Diabetes at ATTD-Asia Conference 2025",
      "url": "https://www.quiverquant.com/news/SAB+Biotherapeutics+to+Present+Data+on+SAB-142+for+Type+1+Diabetes+at+ATTD-Asia+Conference+2025",
      "time_published": "20251208T130925",
      "authors": [
        "NULL"
      ],
      "summary": "SAB Biotherapeutics will present data on its lead program, SAB-142, an immunotherapy for type 1 diabetes, at the ATTD-Asia Conference in Singapore from December 9-11, 2025. The presentations will highlight Phase 1 study findings, including the mechanism of action, immunomodulation without significant side effects, and a favorable safety profile of SAB-142. The company aims to advance SAB-142 into Phase 2b clinical trials to delay T1D progression in newly diagnosed Stage 3 patients.",
      "banner_image": "https://www.quiverquant.com/images/sabs_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.913151"
        }
      ],
      "overall_sentiment_score": 0.347747,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.331778",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management",
      "url": "https://www.globenewswire.com/news-release/2025/12/08/3201467/0/en/SAB-BIO-to-Present-Data-Showcasing-Progress-in-the-Development-of-SAB-142-at-the-Asian-Conference-on-Innovative-Therapies-for-Diabetes-Management.html",
      "time_published": "20251208T130925",
      "authors": [
        "NULL"
      ],
      "summary": "SAB Biotherapeutics, Inc. will extensively present data on SAB-142 at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) in Singapore. The presentations will highlight Phase 1 study data demonstrating the clinically validated, multi-specific mechanism of action, immunomodulation without sustained lymphodepletion, and a favorable safety profile for SAB-142. These findings support SAB-142's development as a potential best-in-class, redosable immunotherapy for delaying Type 1 Diabetes progression in new-onset, Stage 3 patients.",
      "banner_image": "https://ml.globenewswire.com/media/OWExOTZhYzAtYzgzOS00OGJhLTllNWUtNWUwM2MwZGUwZTE3LTEyMzMyOTQtMjAyNS0xMi0wOC1lbg==/tiny/SAB-Biotherapeutics-Inc-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.900143"
        }
      ],
      "overall_sentiment_score": 0.480934,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.473605",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management",
      "url": "https://finance.yahoo.com/news/sab-bio-present-data-showcasing-130000691.html",
      "time_published": "20251208T070000",
      "authors": [
        "NULL"
      ],
      "summary": "SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced it will present data on its lead program, SAB-142, at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) in Singapore. The presentations will highlight Phase 1 study data demonstrating the multi-specific mechanism of action, immunomodulation without sustained lymphodepletion, and a favorable safety profile for SAB-142, a potential best-in-class immunotherapy for delaying Type 1 Diabetes progression. SAB-142 is currently in Phase 2b clinical development.",
      "banner_image": "https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.927351"
        },
        {
          "topic": "finance",
          "relevance_score": "0.620558"
        }
      ],
      "overall_sentiment_score": 0.467352,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "0.983333",
          "ticker_sentiment_score": "0.452626",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of \"Moderate Buy\" by Brokerages",
      "url": "https://www.marketbeat.com/instant-alerts/sab-biotherapeutics-inc-nasdaqsabs-given-consensus-recommendation-of-moderate-buy-by-brokerages-2025-12-04/",
      "time_published": "20251207T210953",
      "authors": [
        "MarketBeat"
      ],
      "summary": "SAB Biotherapeutics, Inc. (NASDAQ:SABS) has received a \"Moderate Buy\" consensus recommendation from five brokerages, with an average one-year price target of $9.33. The company recently reported better-than-expected quarterly earnings and has attracted significant institutional investment, including a new stake from Woodline Partners. Despite the positive analyst outlook, some firms maintain a \"sell\" or \"hold\" rating.",
      "banner_image": "https://www.marketbeat.com/logos/sab-biotherapeutics-logo-1200x675.png?v=20211202075708",
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.906633"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.806938"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.907004"
        }
      ],
      "overall_sentiment_score": 0.266098,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "0.956211",
          "ticker_sentiment_score": "0.269742",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners are individual investors who got richer after stock soared 22% last week",
      "url": "https://finance.yahoo.com/news/sab-biotherapeutics-inc-nasdaq-sabs-122725683.html",
      "time_published": "20251124T051200",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "Individual investors are the largest ownership group in SAB Biotherapeutics (NASDAQ:SABS) with 36%, benefiting significantly from a 22% stock soar last week. Institutional investors hold an 11% stake, while private equity firms control 33% of the company. Hedge funds, including Vivo Capital, LLC, RA Capital Management, L.P., and Commodore Capital LP, collectively hold a substantial portion of shares, influencing key corporate decisions.",
      "banner_image": "NULL",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.924684"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.817567"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.704108"
        }
      ],
      "overall_sentiment_score": 0.323267,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.305084",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Chardan Capital Maintains SAB Biotherapeutics (SABS) Buy Recommendation",
      "url": "https://www.nasdaq.com/articles/chardan-capital-maintains-sab-biotherapeutics-sabs-buy-recommendation",
      "time_published": "20251117T070700",
      "authors": [
        "George Maybach"
      ],
      "summary": "Chardan Capital has reaffirmed its Buy recommendation for SAB Biotherapeutics (NasdaqCM:SABS). Analysts project a significant 157.43% upside, with an average one-year price target of $9.01 per share. Institutional ownership in SABS has also seen a substantial increase, reflecting growing fund sentiment.",
      "banner_image": "https://www.nasdaq.com/sites/acquia.prod/files/2022/05/24/fintel-f-logo.jpg",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.907761"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.828282"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.717211"
        }
      ],
      "overall_sentiment_score": 0.476244,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.492173",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights",
      "url": "https://investingnews.com/sab-bio-reports-third-quarter-financial-results-and-recent-business-highlights/",
      "time_published": "20251117T051200",
      "authors": [
        "Investing News Network"
      ],
      "summary": "SAB Biotherapeutics (Nasdaq: SABS) released its Q3 2025 financial results, highlighting the initiation of its registrational Phase 2b SAFEGUARD trial for SAB-142, a treatment for new-onset, Stage 3 autoimmune T1D. The company also reported a strong cash position of $161.5 million and presented positive clinical data for SAB-142 at recent conferences, reinforcing its potential as a novel immunotherapeutic. Enrollment for the SAFEGUARD trial is ongoing with the first patient expected to be dosed by year-end, and further Phase 1 data, including redosing, is anticipated soon.",
      "banner_image": "https://investingnews.com/media-library/image.gif?id=29654756&width=1200&height=1200",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.910451"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.804686"
        },
        {
          "topic": "finance",
          "relevance_score": "0.644236"
        }
      ],
      "overall_sentiment_score": 0.467188,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.459836",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights",
      "url": "https://www.globenewswire.com/news-release/2025/11/13/3187921/0/en/SAB-BIO-Reports-Third-Quarter-Financial-Results-and-Recent-Business-Highlights.html",
      "time_published": "20251113T170000",
      "authors": [
        "NULL"
      ],
      "summary": "SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced its third-quarter 2025 financial results and business highlights, including the initiation of the registrational Phase 2b SAFEGUARD trial for SAB-142 in type 1 diabetes (T1D). The company reported significant progress in its clinical plans, with multiple trial sites activated and the first patient expected to be dosed by year-end. Financially, SAB BIO reported a strong cash position of $161.5 million, providing an operational runway through 2028, and a net income of $45.4 million for the quarter.",
      "banner_image": "https://ml.globenewswire.com/media/Y2E1OWY2NzItNTEwOC00NGZiLThiNjUtYjVjMDM5Zjk1MDAzLTEyMzMyOTQtMjAyNS0xMS0xMy1lbg==/tiny/SAB-Biotherapeutics-Inc-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.611047"
        }
      ],
      "overall_sentiment_score": 0.601428,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.624848",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB Biotherapeutics Initiates Phase 2b SAFEGUARD Trial for SAB-142 in Autoimmune Type 1 Diabetes Patients",
      "url": "https://www.quiverquant.com/news/SAB+Biotherapeutics+Initiates+Phase+2b+SAFEGUARD+Trial+for+SAB-142+in+Autoimmune+Type+1+Diabetes+Patients",
      "time_published": "20251113T101100",
      "authors": [
        "NULL"
      ],
      "summary": "SAB Biotherapeutics has initiated its Phase 2b SAFEGUARD trial for SAB-142, a treatment for new-onset Stage 3 autoimmune type 1 diabetes, with the first patient expected to be dosed by year-end. The company presented positive Phase 1 data, highlighting SAB-142's promising safety profile and immunomodulatory mechanism. With a strong financial position, SAB Biotherapeutics is fully funded through 2028 to complete this registrational study, aiming to redefine T1D treatment by delaying disease progression.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.948140"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.932041"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.606689"
        }
      ],
      "overall_sentiment_score": 0.444132,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.413932",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142",
      "url": "https://www.globenewswire.com/news-release/2025/11/04/3180353/0/en/SAB-BIO-to-Present-Data-at-the-International-Society-for-Pediatric-and-Adolescent-Diabetes-Annual-Conference-Showcasing-Progress-in-the-Development-of-SAB-142.html",
      "time_published": "20251104T083000",
      "authors": [
        "NULL"
      ],
      "summary": "SAB Biotherapeutics, Inc. plans to present six scientific presentations at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD), detailing the progress of its lead program, SAB-142, for delaying type 1 diabetes progression. The presentations will include data on SAB-142's multi-specific mechanism of action, favorable safety profile from its Phase 1 trial, and details of a novel pharmacokinetic assay. This data supports SAB-142's potential as a best-in-class therapy for Stage 3 autoimmune type 1 diabetes.",
      "banner_image": "https://ml.globenewswire.com/media/YWNmYjIwNjMtMGFlNC00YjZjLTg5NzMtNWQ0NWUwZmNjYjdjLTEyMzMyOTQtMjAyNS0xMS0wNC1lbg==/tiny/SAB-Biotherapeutics-Inc-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.942114"
        }
      ],
      "overall_sentiment_score": 0.469643,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.490613",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB BIO to Participate in Upcoming Investor Conferences",
      "url": "https://www.globenewswire.com/news-release/2025/11/04/3180281/0/en/SAB-BIO-to-Participate-in-Upcoming-Investor-Conferences.html",
      "time_published": "20251104T080000",
      "authors": [
        "NULL"
      ],
      "summary": "SAB Biotherapeutics, Inc. will participate in several investor conferences in November and December 2025 across various locations. The company, a clinical-stage biopharmaceutical firm, will have members of its management team present at the UBS Global Healthcare Conference, Guggenheim Second Annual Healthcare Innovation Conference, and the 8th Annual Evercore Healthcare Conference. They will discuss their lead program, SAB-142, which is in clinical development for delaying the progression of type 1 diabetes.",
      "banner_image": "https://ml.globenewswire.com/media/NTcwZGZlZTctMjFhMC00ZmRjLThkZmItY2M0MzQ0MjI5MmY0LTEyMzMyOTQtMjAyNS0xMS0wNC1lbg==/tiny/SAB-Biotherapeutics-Inc-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.917334"
        },
        {
          "topic": "finance",
          "relevance_score": "0.729349"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.614834"
        }
      ],
      "overall_sentiment_score": 0.269305,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.292454",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142",
      "url": "https://investingnews.com/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142/",
      "time_published": "20251104T051200",
      "authors": [
        "Investing News Network"
      ],
      "summary": "SAb Biotherapeutics, Inc. (Nasdaq: SABS) will present data from its lead program, SAB-142, for type 1 diabetes (T1D) at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD). The presentations will highlight clinical progress, safety data, and a novel pharmacokinetic assay for SAB-142, which is being developed to delay T1D progression in new-onset Stage 3 patients. The company aims to position SAB-142 as a potential best-in-class therapy for autoimmune type 1 diabetes, based on its multispecific mechanism of action and favorable safety profile.",
      "banner_image": "https://investingnews.com/media-library/image.gif?id=29654756&width=1200&height=1200",
      "source": "Investing News Network",
      "category_within_source": "General",
      "source_domain": "Investing News Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.040246,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "0.307629",
          "ticker_sentiment_score": "0.033438",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SAb Biotherapeutics, Inc. : Quotes, Address, Contact",
      "url": "https://www.news-medical.net/suppliers/SAb-Biotherapeutics-Inc.aspx",
      "time_published": "20251103T000000",
      "authors": [],
      "summary": "SAb Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on immune and autoimmune disorders, listed on NASDAQ (SABS) since 2021. The company utilizes an innovative genetic engineering platform to produce human immunoglobulins and has conducted seven clinical trials. Their lead investigational candidate, SAB-142, is a novel therapy for type 1 diabetes, currently undergoing Phase 1 clinical trials with positive topline results.",
      "banner_image": null,
      "source": "News-Medical",
      "category_within_source": "General",
      "source_domain": "News-Medical",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.439522,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.400442",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SAB Biotherapeutics (NASDAQ:SABS) Receives \u201cSell (E+)\u201d Rating from Weiss Ratings - Defense World",
      "url": "https://www.defenseworld.net/2025/10/15/sab-biotherapeutics-nasdaqsabs-receives-sell-e-rating-from-weiss-ratings.html",
      "time_published": "20251015T063923",
      "authors": [
        "Defense World Staff"
      ],
      "summary": "SAB Biotherapeutics (NASDAQ:SABS) recently received a \"Sell (E+)\" rating from Weiss Ratings. This comes after HC Wainwright lowered its price target for SABS from $10.00 to $9.00 but maintained a \"buy\" rating. Institutional investor HB Wealth Management LLC increased its stake in SAB Biotherapeutics during the second quarter.",
      "banner_image": null,
      "source": "Defense World",
      "category_within_source": "General",
      "source_domain": "Defense World",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.949359"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.730984"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.618497"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.525904"
        }
      ],
      "overall_sentiment_score": 0.013565,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "0.316540",
          "ticker_sentiment_score": "0.045666",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SABS Stock Price and Chart \u2014 NASDAQ:SABS",
      "url": "https://www.tradingview.com/symbols/NASDAQ-SABS/",
      "time_published": "20241231T235959",
      "authors": [],
      "summary": "This article provides a comprehensive overview of SAB Biotherapeutics, Inc. (NASDAQ: SABS), including its current stock price, historical performance, key financial metrics, and company information. It details upcoming earnings dates, analyst ratings, and frequently asked questions about the stock's volatility and market capitalization.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.912923"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.942367"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.807848"
        }
      ],
      "overall_sentiment_score": 0.117727,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.145164",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates",
      "url": "https://www.stocktitan.net/news/SABS/sab-bio-announces-second-quarter-2024-financial-results-and-provides-kbk9lnl0xplj.html",
      "time_published": "20240808T175100",
      "authors": [],
      "summary": "SAB BIO (Nasdaq: SABS) released its Q2 2024 financial results, reporting a net loss of $7.3 million and a cash position of $37.3 million as of June 30, 2024. Key updates include FDA clearance for the SAB-142 IND application, the appointment of Lucy To as CFO, and the founding of a new Clinical Advisory Board focused on type 1 diabetes. The company reaffirmed its cash runway into 2026 and expects topline Phase 1 data for SAB-142 by year-end, which is being developed to delay or stop type 1 diabetes progression.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.924176"
        }
      ],
      "overall_sentiment_score": 0.185197,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.198875",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "SAb Biotherapeutics Rebrands as SAB BIO",
      "url": "https://www.globenewswire.com/news-release/2024/06/20/2901581/0/en/SAb-Biotherapeutics-Rebrands-as-SAB-BIO.html",
      "time_published": "20240620T072000",
      "authors": [],
      "summary": "SAb Biotherapeutics has rebranded as SAB BIO, unveiling a new name, logo, and website to better align with its mission to treat and prevent immune and autoimmune disorders, particularly focusing on type 1 diabetes. The company's lead candidate, SAB-142, an immunotherapy for delaying the onset or progression of type 1 diabetes, will be further discussed at the American Diabetes Association 84th Scientific Sessions. SAB BIO also confirmed its fiscal year 2024 outlook and upcoming milestones, including topline data for SAB-142 from its Phase 1 study.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.153326,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.326686",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BMY",
          "relevance_score": "0.510973",
          "ticker_sentiment_score": "0.100954",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.551442",
          "ticker_sentiment_score": "0.146965",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "AMGN",
          "relevance_score": "0.531009",
          "ticker_sentiment_score": "0.129023",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "MRNA",
          "relevance_score": "0.547179",
          "ticker_sentiment_score": "0.141344",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SAB Biotherapeutics CFO Michael King to Depart",
      "url": "https://www.citybiz.co/article/561449/sab-biotherapeutics-cfo-michael-king-to-depart/",
      "time_published": "20240530T000000",
      "authors": [],
      "summary": "Michael King, CFO of SAB Biotherapeutics (Nasdaq: SABS), is departing the company effective June 4 to become CEO of a privately-held oncology company. He will remain an advisor through the end of the year, while Mark Conley, VP of Finance, will serve as Interim CFO during the search for a permanent replacement. The company reaffirmed its 2024 fiscal outlook and upcoming milestones for its lead candidate, SAB-142.",
      "banner_image": null,
      "source": "citybiz",
      "category_within_source": "General",
      "source_domain": "citybiz",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.938670"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.627422"
        },
        {
          "topic": "finance",
          "relevance_score": "0.609564"
        }
      ],
      "overall_sentiment_score": 0.007087,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "0.302370",
          "ticker_sentiment_score": "0.015849",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Pharma company moves headquarters from Midwest to Miami Beach",
      "url": "https://www.bizjournals.com/southflorida/news/2024/05/25/biotech-company-moves-headquarters-miami-beach.html",
      "time_published": "20240525T000000",
      "authors": [
        "Ashley Portero"
      ],
      "summary": "SAB Bio, a public pharmaceutical company, has relocated its headquarters from the Midwest to Miami Beach. The company also announced that it has received FDA clearance to commence a new clinical trial. This move marks a significant update for the company's operational base and research activities.",
      "banner_image": null,
      "source": "The Business Journals",
      "category_within_source": "General",
      "source_domain": "The Business Journals",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929005"
        },
        {
          "topic": "real_estate",
          "relevance_score": "0.744029"
        }
      ],
      "overall_sentiment_score": 0.269075,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.345919",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GEHC",
          "relevance_score": "0.609868",
          "ticker_sentiment_score": "0.213316",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "BSX",
          "relevance_score": "0.615701",
          "ticker_sentiment_score": "0.219074",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "JNJ",
          "relevance_score": "0.647020",
          "ticker_sentiment_score": "0.226848",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.623656",
          "ticker_sentiment_score": "0.243795",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "SAB Biotherapeutics announces new CEO",
      "url": "https://siouxfalls.business/sab-biotherapeutics-announces-new-ceo/",
      "time_published": "20240214T000000",
      "authors": [
        "Staff"
      ],
      "summary": "SAB Biotherapeutics Inc. has appointed Samuel Reich as its new CEO. Reich, who previously served as executive chairman, will continue in that role while co-founder Eddie Sullivan transitions to president. The change aims to optimize the organizational structure as the clinical-stage biopharmaceutical company progresses its lead product candidate, SAB-142, for Type 1 diabetes.",
      "banner_image": null,
      "source": "SiouxFalls.Business",
      "category_within_source": "General",
      "source_domain": "SiouxFalls.Business",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.933613"
        },
        {
          "topic": "finance",
          "relevance_score": "0.648315"
        }
      ],
      "overall_sentiment_score": 0.432965,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "0.973952",
          "ticker_sentiment_score": "0.410903",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Meet South Dakota couple who became quiet force behind state\u2019s newest public company",
      "url": "https://siouxfalls.business/meet-south-dakota-couple-who-became-quiet-force-behind-states-newest-public-company/",
      "time_published": "20211108T211124",
      "authors": [
        "Jodi Schwan"
      ],
      "summary": "Eddie and Christine Hamilton, a South Dakota couple, were instrumental in the development and public listing of SAB Biotherapeutics, a company that utilizes genetically developed cows to produce human immune responses for targeted diseases. Their long-standing involvement, from early investment to board membership, helped guide the biotech firm through its challenges, including the COVID-19 pandemic response, and its eventual Nasdaq listing. The Hamiltons emphasize their commitment to growing the company in South Dakota, highlighting the state's suitability for their unique bovine-based research and development.",
      "banner_image": null,
      "source": "SiouxFalls.Business",
      "category_within_source": "General",
      "source_domain": "SiouxFalls.Business",
      "topics": [
        {
          "topic": "ipo",
          "relevance_score": "0.924914"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.803003"
        },
        {
          "topic": "finance",
          "relevance_score": "0.618560"
        }
      ],
      "overall_sentiment_score": 0.849081,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "SABS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.822330",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}